Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell (Nasdaq: ICCC) reported unaudited Q1 2026 net income of $1.9 million, or $0.21 per share, on product sales of $10.4 million, up 28.4% year over year.
Gross margin reached 45.0%. Cash rose to $6.8 million, supported by $3.4 million free cash flow, higher manufacturing output, and a $2 million settlement to fund First Defense® capacity expansion.
ImmuCell (Nasdaq: ICCC) will report unaudited results for the quarter ended March 31, 2026 after market close on May 14, 2026 and plans a conference call on May 15, 2026 at 9:00 AM ET.
ImmuCell expects no change to preliminary sales disclosed April 8, 2026, and intends to file its Form 10-Q on May 14, 2026 after market close.
ImmuCell (Nasdaq: ICCC) announced two board appointments and a governance restructure effective April 15, 2026. Dr. Gilles Guillemette and Dr. Anthony DiMarco join the board; the company will move to a seven-person board with six independent directors and create a Strategy and Technology Committee.
The new committee will be chaired by Dr. Guillemette and includes members focused on manufacturing yield, capacity expansion, and innovation-driven growth of the First Defense® product line.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited Q1 2026 product sales of $10.4 million, a 28.4% increase versus Q1 2025. Domestic sales rose 35.7% to $9.7 million while Tri-Shield First Defense sales grew 38.5% to $7.9 million; international sales fell 30.2%.
The company cited seasonal demand, inventory and manufacturing actions, and ongoing backorder effects. A conference call is scheduled for May 15, 2026 at 9:00 AM ET.
ImmuCell (Nasdaq: ICCC) appointed Kathy Turner to its Board of Directors effective April 1, 2026, replacing retiring director Steven Rosgen. Turner will chair the Compensation and Stock Option Committee and join the Audit Committee.
She brings 30+ years of global commercial leadership across animal health and healthcare, including prior board service at Elanco and senior roles at IDEXX and Abbott, and will support expansion of the First Defense® product internationally.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the year ended December 31, 2025 showing product sales of $27.6M, up 4.3% year-over-year, and a gross profit margin of 41.4% versus 30.0% in 2024. Net loss narrowed to $1.0M, or ($0.12) per share.
Management cited higher volumes, manufacturing efficiencies and price realization; cash was $3.8M, inventory rose to $9.267M, and net working capital was $12.967M as of December 31, 2025.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.
Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q4 and full-year 2025. Q4 product sales were $7.6 million (down 1.6% year-over-year) with domestic $7.0M (+8.7%), international $0.62M (-52.6%), Tri-Shield $6.0M (+41.3%) and Dual-Force/other $1.7M (-53.0%). FY 2025 sales were $27.6M (+4.3%) with Tri-Shield $19.9M (+26.5%) and Dual-Force $7.7M (-28.2%).
The company received an FDA Incomplete Letter for Re-Tain (Dec 23, 2025), paused further Re-Tain investment and expects an approx. $2.9M non-cash impairment for Re-Tain assets and total Q4 write-downs of $3.6M. Management plans to repurpose most Re-Tain assets for First Defense and expand the sales force by 50%.
ImmuCell (Nasdaq: ICCC) will hold an investor conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss its strategic shift in focus to the First Defense product line and away from Re-Tain, plus unaudited topline sales for the quarter and year ended December 31, 2025. The company will release those topline sales after market close on Thursday, January 8, 2026.
ImmuCell also plans to release full unaudited financial results for the quarter and year on Wednesday, February 25, 2026 with a follow-up call on Thursday, February 26, 2026 at 9:00 AM ET. Dial-in numbers and replay access codes are provided for both calls.
ImmuCell (Nasdaq: ICCC) received an FDA Incomplete Letter for its Re-Tain NADA on December 23, 2025 after four of five technical sections were deemed complete and the contract manufacturer failed to satisfactorily address inspectional deficiencies. ImmuCell will pause further investment in Re-Tain, complete ongoing investigational studies, and pursue licensing or partnering options that avoid further capital or in-house manufacturing expenditure.
ImmuCell is simultaneously increasing First Defense field sales by 50%, expanding First Defense manufacturing, and expects a ~$2.3 million estimated non-cash impairment in Q4 2025 (Re-Tain net book value was $15.5M as of Sept 30, 2025). First Defense reported $27.8M TTM revenue and holds a 29% U.S. spend share in scour prevention; company estimates a $900M worldwide TAM for scours prevention.